These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20596117)

  • 1. [An elderly man with known heart failure admitted with cardiogenic shock].
    Hovland A; Fagerheim AK; Hardersen R; Nielsen EW
    Tidsskr Nor Laegeforen; 2010 Jul; 130(13):1352-4. PubMed ID: 20596117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hyperkalemia, heart failure and reduced renal function].
    Bugge JF
    Tidsskr Nor Laegeforen; 2010 Jul; 130(13):1354-5. PubMed ID: 20596118
    [No Abstract]   [Full Text] [Related]  

  • 3. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
    Erden I; Yalcin S; Ozhan H
    Kardiol Pol; 2010 Sep; 68(9):1043-5; discussion 1046. PubMed ID: 20859899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A patient with severe hyperkalaemia -- an emergency after RALES].
    Nürnberger J; Daul A; Philipp T
    Dtsch Med Wochenschr; 2005 Sep; 130(36):2008-11. PubMed ID: 16143930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
    N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H; Moukarbel GV; Dawson B; Hajjar RJ; Francis GS
    Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 13. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
    Schepkens H; Vanholder R; Billiouw JM; Lameire N
    Am J Med; 2001 Apr; 110(6):438-41. PubMed ID: 11331054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
    Fujii H; Nakahama H; Yoshihara F; Nakamura S; Inenaga T; Kawano Y
    Kobe J Med Sci; 2005; 51(1-2):1-6. PubMed ID: 16199929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of heart failure with spironolactone--trial and tribulations.
    McMurray JJ; O'Meara E
    N Engl J Med; 2004 Aug; 351(6):526-8. PubMed ID: 15295043
    [No Abstract]   [Full Text] [Related]  

  • 19. [Renal effect of treatment for heart failure].
    Rasmussen ZZ; Barfod T; Klit J
    Ugeskr Laeger; 2009 Feb; 171(9):718. PubMed ID: 19257999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute renal failure due to RAAS-inhibitors combined with dehydration].
    Scherpbier ND; de Grauw WJ; Wetzels JF; Vervoort GM
    Ned Tijdschr Geneeskd; 2010; 154():A1548. PubMed ID: 20699027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.